These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21129462)

  • 1. Particle formation of budesonide from alcohol-modified subcritical water solutions.
    Carr AG; Mammucari R; Foster NR
    Int J Pharm; 2011 Feb; 405(1-2):169-80. PubMed ID: 21129462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Excipient-free nanoporous microparticles of budesonide for pulmonary delivery.
    Nolan LM; Tajber L; McDonald BF; Barham AS; Corrigan OI; Healy AM
    Eur J Pharm Sci; 2009 Jul; 37(5):593-602. PubMed ID: 19463948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Budesonide Particles for Dry Powder Inhalation Prepared Using a Microfluidic Reactor Coupled With Ultrasonic Spray Freeze Drying.
    Saboti D; Maver U; Chan HK; Planinšek O
    J Pharm Sci; 2017 Jul; 106(7):1881-1888. PubMed ID: 28285981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhalable co-amorphous budesonide-arginine dry powders prepared by spray drying.
    Lu W; Rades T; Rantanen J; Yang M
    Int J Pharm; 2019 Jun; 565():1-8. PubMed ID: 30999050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effervescent dry powder for respiratory drug delivery.
    Ely L; Roa W; Finlay WH; Löbenberg R
    Eur J Pharm Biopharm; 2007 Mar; 65(3):346-53. PubMed ID: 17156987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of primary crystallisation conditions on the mechanical and interfacial properties of micronised budesonide for dry powder inhalation.
    Kubavat HA; Shur J; Ruecroft G; Hipkiss D; Price R
    Int J Pharm; 2012 Jul; 430(1-2):26-33. PubMed ID: 22449413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and aerodynamic evaluation of spray dried recombinant human growth hormone using protein stabilizing agents.
    Jalalipour M; Gilani K; Tajerzadeh H; Najafabadi AR; Barghi M
    Int J Pharm; 2008 Mar; 352(1-2):209-16. PubMed ID: 18164150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisolvent crystallization of pharmaceutical excipients from aqueous solutions and the use of preferred orientation in phase identification by powder X-ray diffraction.
    Crisp JL; Dann SE; Blatchford CG
    Eur J Pharm Sci; 2011 Apr; 42(5):568-77. PubMed ID: 21382490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of carrier surface treatment on drug particle detachment from crystalline carriers in adhesive mixtures for inhalation.
    Dickhoff BH; de Boer AH; Lambregts D; Frijlink HW
    Int J Pharm; 2006 Dec; 327(1-2):17-25. PubMed ID: 16920287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhalation performance of pollen-shape carrier in dry powder formulation with different drug mixing ratios: comparison with lactose carrier.
    Hassan MS; Lau R
    Int J Pharm; 2010 Feb; 386(1-2):6-14. PubMed ID: 19922775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of inhalable dry powder formulation of basic fibroblast growth factor.
    Ibrahim BM; Jun SW; Lee MY; Kang SH; Yeo Y
    Int J Pharm; 2010 Jan; 385(1-2):66-72. PubMed ID: 19853028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large porous particles for respiratory drug delivery. Glycine-based formulations.
    Ogienko AG; Bogdanova EG; Trofimov NA; Myz SA; Ogienko AA; Kolesov BA; Yunoshev AS; Zubikov NV; Manakov AY; Boldyrev VV; Boldyreva EV
    Eur J Pharm Sci; 2017 Dec; 110():148-156. PubMed ID: 28479348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhalation performance of pollen-shape carrier in dry powder formulation: effect of size and surface morphology.
    Hassan MS; Lau R
    Int J Pharm; 2011 Jul; 413(1-2):93-102. PubMed ID: 21540087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physical characteristics and aerosol performance of naringin dry powders for pulmonary delivery prepared by spray-drying.
    Sansone F; Aquino RP; Del Gaudio P; Colombo P; Russo P
    Eur J Pharm Biopharm; 2009 May; 72(1):206-13. PubMed ID: 18996478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary deposition of lactose carriers used in inhalation powders.
    Karhu M; Kuikka J; Kauppinen T; Bergström K; Vidgren M
    Int J Pharm; 2000 Feb; 196(1):95-103. PubMed ID: 10675711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants.
    Cheow WS; Ng ML; Kho K; Hadinoto K
    Int J Pharm; 2011 Feb; 404(1-2):289-300. PubMed ID: 21093560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of physical and inhalation properties of spray-dried and micronized terbutaline sulphate.
    Thi TH; Danède F; Descamps M; Flament MP
    Eur J Pharm Biopharm; 2008 Sep; 70(1):380-8. PubMed ID: 18504120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of water to ethanol feed ratio on physical properties and aerosolization behavior of spray dried cromolyn sodium particles.
    Gilani K; Najafabadi AR; Barghi M; Rafiee-Tehrani M
    J Pharm Sci; 2005 May; 94(5):1048-59. PubMed ID: 15793812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations.
    Schüle S; Friess W; Bechtold-Peters K; Garidel P
    Eur J Pharm Biopharm; 2007 Jan; 65(1):1-9. PubMed ID: 17034996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.